Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for stopping by. Welcome to the Akibia second quarter 2025 financial results. At this time, all participants are in listening only mode. After the speakers presentation, we'll open up for questions. To ask a question during the session, you will need to press star one one on your telephone. You'll then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's call is being recorded. I would now like to hand the conference over to your speaker, Mercedes Carrasco, senior director of investor relations. Please go ahead. Thank you and welcome to Akibia's second quarter 2025 financial results and business updates conference call. Please note that a press release was issued earlier today, Thursday, August 7th, detailing our second quarter 2025 financial results. And that release is available on the investor sections of our website. For your convenience, a replay of today's call will also be available on our website after we conclude. Joining me for today's call, we have John Butler, chief executive officer, Nick Grunz, chief commercial officer, and Eric Ostrowski, chief financial and chief business officer. I'd like to remind everyone that this call includes forward-looking statements. Each forward-looking statement on this call is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. Additional information describing these risks is included in the financial results press release that we issued on August 7th, as well as in the risk factors and management discussion and analysis section of our most recent annual and quarterly reports filed with the SEC. With that, I'd like to introduce our...